Health Canada approves Brukinsa (zanubrutinib) for the treatment of Waldenström’s macroglobulinaemia

2 March 2021 - Approval is based on the Phase 3 ASPEN trial of Brukinsa compared to ibrutinib. ...

Read more →

Health Canada approves AstraZeneca's COVID-19 vaccine

26 February 2021 - Canada's regulator estimates vaccine's efficacy at 62.1 per cent. ...

Read more →

Emgality (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache

25 February 2021 - The first and only anti-CGRP treatment with dual indications. ...

Read more →

Medexus announces expanded availability of Gleolan in Canada

25 February 2021 - Medexus Pharmaceuticals announced today that it has initiated the commercial launch of Gleolan in Canada, which had ...

Read more →

Bladder cancer drug shortage resolved with Health Canada approval

24 February 2021 - Verity-BCG bladder cancer treatment available for Canadian patients in the spring. ...

Read more →

Health Canada approves Dupixent (dupilumab) as the first biologic for the treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years

23 February 2021 - Dupixent is the only biologic medicine approved to treat atopic dermatitis for this patient population. ...

Read more →

Viatris launches Hulio (adalimumab biosimilar) in Canada

18 February 2021 - Viatris announced today that Health Canada has approved Hulio, and product is now available in Canada. ...

Read more →

Health Canada approves Reblozyl (luspatercept), new class of treatment for adult patients living with myelodysplastic syndromes

16 February 2021 - Reblozyl, an erythroid maturation agent, is the first and only of its kind approved for use in ...

Read more →

Health Canada authorises Dayvigo (lemborexant)

4 February 2021 - Now available in Canada for the treatment of insomnia in adults. ...

Read more →

Celltrion Healthcare receives Health Canada marketing authorization for world's first subcutaneous formulation of infliximab, Remsima SC, for the treatment of people with rheumatoid arthritis

1 February 2021 - This novel formulation provides an alternative administration option for Canadian physicians and their patients. ...

Read more →

Health Canada approves Imbruvica (ibrutinib) plus rituximab for the treatment of patients with chronic lymphocytic leukaemia

13 January 2021 - Patients aged 70 or younger with previously untreated CLL lived longer without disease progression compared to patients ...

Read more →

Health Canada approves Onureg (azacitidine tablets), first maintenance therapy for patients in remission from acute myeloid leukaemia

12 January 2021 - Onureg has shown clinically meaningful increase in overall survival for patients. ...

Read more →

Health Canada approves Lundbeck's Vyepti (eptinezumab)--the first and only intravenous preventive treatment for migraine

12 January 2021 - Lundbeck is pleased to announce that Vyepti (eptinezumab) has been approved by Health Canada for the preventive ...

Read more →

Health Canada approves Bavencio for the maintenance treatment of patients with advanced bladder cancer

11 January 2021 - Bavencio is the first and only maintenance therapy for unresectable locally advanced or metastatic urothelial carcinoma ...

Read more →

KYE Pharmaceuticals announces approval of Corzyna in Canada (ranolazine extended release tablets)

5 January 2020 - KYE Pharmaceuticals today announced an important milestone, Corzyna (ranolazine extended release tablets) has now been approved by ...

Read more →